| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/12/2005 | CN1184315C Death domain containing receptor 5 |
| 01/12/2005 | CN1184313C Novel protein derived from agkistrodon saxatilis emelianov and process for preparing the same |
| 01/12/2005 | CN1184310C Combined deletion 19 Kda, 55KDA, E1B code sequence recombination adenovirus construction body and its use |
| 01/12/2005 | CN1184233C Erytrocyte-stimulating factor coupling |
| 01/12/2005 | CN1184232C Human tumor necrosin relative death inducing ligand mutein and its prepn process and medicine composition |
| 01/12/2005 | CN1184219C Taxusane phoshponic oxygen methyl ether derivant |
| 01/12/2005 | CN1184208C Substituted benzimidazoles and their prepn. and use |
| 01/12/2005 | CN1184200C Bi-aromatic compounds bond by a heteroethynytene radical and pharmaceutical and comsmetic compositions containing same |
| 01/12/2005 | CN1184196C Substituted benzoylguanidines, method for their production, their use as medicament or diagnostic agent and mediciment containing same |
| 01/12/2005 | CN1183959C Tumor suppressing polypeptide TSF and gene therapy vector composition |
| 01/12/2005 | CN1183952C Medicine for treating uterus myoma disease and its preparation method |
| 01/12/2005 | CN1183938C Chinese medicine prepn for expelling toxin and resisting cancer and its preparing method and use |
| 01/12/2005 | CN1183919C Cancer treating medical composition |
| 01/12/2005 | CN1183914C Use of N-acetyl-D-aminoglucose in preparation of anti-tumor and anti-tumor-transition medicines |
| 01/11/2005 | US6841674 N-heterocyclic derivatives as NOS inhibitors |
| 01/11/2005 | US6841673 Enzyme inhibitors; antiinflammatory agents; rheumatic diseases; antidiabetic agents |
| 01/11/2005 | US6841617 Thermogelling biodegradable aqueous polymer solution |
| 01/11/2005 | US6841579 To screen for inhibitors of cell growth and to develop small molecule therapeutics for treating cancers |
| 01/11/2005 | US6841568 Inducing contraception, treat progesterone-related carcinomas and adenocarcinomas; hormone replacement therapy |
| 01/11/2005 | US6841567 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 01/11/2005 | US6841564 Tri-aryl-substituted-ethane PDE4 inhibitors |
| 01/11/2005 | US6841548 Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives |
| 01/11/2005 | US6841545 Heat resistance; anticancer drug |
| 01/11/2005 | US6841538 Combination therapy using nucleic acids and radio therapy |
| 01/11/2005 | US6841530 Semi-synthetic studies toward didemnin analogues |
| 01/11/2005 | US6841381 Immunization by inoculation of DNA transcription unit |
| 01/11/2005 | US6841355 Positioning solid support into injury; wound healing agents; peptide |
| 01/11/2005 | US6841177 Pharmacological activities of curcuma longa extracts |
| 01/11/2005 | CA2267670C Method for preparing human stem cell factor polypeptide |
| 01/08/2005 | CA2469089A1 En-2 gene, disgnostic and therapeutic uses thereof |
| 01/07/2005 | CA2470768A1 Crystal structure of osc |
| 01/07/2005 | CA2434995A1 Oncolytic viruses for the treatment of neoplasms having activated pp2a or rac |
| 01/06/2005 | WO2005001778A2 Biologically active neopeltolide compounds |
| 01/06/2005 | WO2005001732A1 Medical care self-cell delivery support system, medical care self-cell delivery support financial system, and their methods |
| 01/06/2005 | WO2005001117A1 Method of selecting wt1 vaccine adaptive patient |
| 01/06/2005 | WO2005001038A2 Recombinant anti-cd30 antibodies and uses thereof |
| 01/06/2005 | WO2005000900A1 Treatment with anti-vegf antibodies |
| 01/06/2005 | WO2005000889A1 Immunogenic peptides for the treatment of prostate and breast cancer |
| 01/06/2005 | WO2005000887A1 Rasgap derived peptide for selectively killing cancer cells |
| 01/06/2005 | WO2005000852A2 Product containing at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent |
| 01/06/2005 | WO2005000843A2 Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof |
| 01/06/2005 | WO2005000834A1 Pentafluoroalkanesulfinyl naphthalenes and related estrogen receptor modulators |
| 01/06/2005 | WO2005000818A1 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
| 01/06/2005 | WO2005000778A1 Hsp90 FAMILY PROTEIN INHIBITORS |
| 01/06/2005 | WO2005000355A1 Treatment of tumor by cotransferring chemotherapeutic agent with cytokine gene |
| 01/06/2005 | WO2005000348A2 Vaccines inducing nkt-cell and toll-like-receptor activation |
| 01/06/2005 | WO2005000342A1 Peptides derived from the protein mmp-2, and the use thereof in antitumoral immunotherapy |
| 01/06/2005 | WO2005000341A1 Use of cytosolic phospholipid hydroperoxide glutathione peroxidase to reduce tumor growth |
| 01/06/2005 | WO2005000332A2 Therapeutic agent for soft tissue sarcoma |
| 01/06/2005 | WO2005000320A2 Use of double-stranded ribonucleic acid for inducing cell lysis |
| 01/06/2005 | WO2005000318A2 Method of inducing apoptosis and inhibiting cardiolipin synthesis |
| 01/06/2005 | WO2005000304A1 Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors |
| 01/06/2005 | WO2005000303A1 Pyrazolo`3,4-b!pyridin-6-ones as gsk-3 inhibitors |
| 01/06/2005 | WO2005000300A1 Substituted 5-membered ring compounds and their use |
| 01/06/2005 | WO2005000292A1 Cancer treatment with epothilones |
| 01/06/2005 | WO2005000289A1 Topical use of valproic acid for the prevention or treatment of skin disorders |
| 01/06/2005 | WO2005000282A2 Inhibitors of histone deacetylases for the suppression therapy of diseases |
| 01/06/2005 | WO2005000266A2 Liposomal formulations comprising a combination of two or more active agents |
| 01/06/2005 | WO2005000240A2 Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis |
| 01/06/2005 | WO2005000235A2 NUCLEIC ACID SEQUENCES ENCODING AND COMPOSITIONS COMPRISING IgE SIGNAL PEPTIDE AND/OR IL-15 AND METHODS FOR USING THE SAME |
| 01/06/2005 | WO2005000042A1 Composition containing lactic acid bacterium producing equol |
| 01/06/2005 | WO2004099193A3 1-aryl-3-(indol-5-yl)-prop-2-en-1-ones, compositions comprising the same and use thereof |
| 01/06/2005 | WO2004098620A8 Activated carbon infusion solution, preparation method therefor and use thereof for the manufacture of drug for treating cancer |
| 01/06/2005 | WO2004087756A3 Antibodies against insulin-like growth factor i receptor and uses thereof |
| 01/06/2005 | WO2004087646A3 Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor xa in the treatment of thrombo-embolic diseases |
| 01/06/2005 | WO2004082574A3 Diagnostics and therapeutics for diseases associated with dopamine receptor d5 (drd5) |
| 01/06/2005 | WO2004076445A3 Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis |
| 01/06/2005 | WO2004073595A3 Novel purine derivatives, preparation method thereof, application of same as medicaments, pharmaceutical compositions and novel use |
| 01/06/2005 | WO2004072117A3 Antibodies to c-met for the treatment of cancers |
| 01/06/2005 | WO2004071382A3 Substituted heterocycles |
| 01/06/2005 | WO2004071378A3 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a) |
| 01/06/2005 | WO2004052873A3 Analogs of green tea polyphenols as chemotherapeutic and chemopreventive agents |
| 01/06/2005 | WO2004042342A3 Nuclear pore protein nup88 as a novel target |
| 01/06/2005 | WO2004019959A3 Dna repair enzymes |
| 01/06/2005 | WO2003050255A3 Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer |
| 01/06/2005 | WO2003032907A9 High-concentration protein formulations and method of manufacture |
| 01/06/2005 | WO2002055700A8 Human genes and gene expression products isolated from human prostate |
| 01/06/2005 | US20050004510 Noninvasive vascular therapy |
| 01/06/2005 | US20050004360 Compounds and methods for modulation of estrogen receptors |
| 01/06/2005 | US20050004358 Formed by treatment with isopropyl alcohol and elimination of lipophilic substances; fermentation, centrifugation, and ultrafiltration |
| 01/06/2005 | US20050004352 Single-chain multiple antigen-binding molecule, its preparation and use |
| 01/06/2005 | US20050004348 Sodium transport protein for use as tool in identifying modulator for treatment of hyperphosphatemia or hypophosphatemia |
| 01/06/2005 | US20050004227 Cell growth inhibitor |
| 01/06/2005 | US20050004207 Substituted isoindoles and the use thereof |
| 01/06/2005 | US20050004204 2-Iminopyrrolidine derivatives |
| 01/06/2005 | US20050004202 Such as 3-[1-(3-methoxypropyl )-1H-indazol-3-yl]-4-[1-(3-pyridinyl )-1H-indol-3-yl]-1H-pyrrole-2,5-dione; protein kinase C and/or glycogen synthase kinase-3 diseases |
| 01/06/2005 | US20050004197 Thrombin receptors antagonists; oral efficacy |
| 01/06/2005 | US20050004195 Inhibitors of phosphoinositide 3 kinases; inflammatory diseases, cardiovascular disorders, cancers; such as 5,6-dimethoxy-3-o-tolylsulfanyl-1H-indole-2-carboxylic acid-(2H-tetrazol-5-yl)-amide |
| 01/06/2005 | US20050004186 Phenyl-(2-[1,3,4]thiadiazol-2-yl-phenyl)-amine and (2-[1,3,4]Oxadiazol-2-yl-phenyl)phenyl-amine derivatives; immunomodulators; inflammation, proliferative diseases |
| 01/06/2005 | US20050004180 Conditions mediated by beta chemokine receptor 2, monocyte chemotactic protein 1 and/or their interaction; such as 4-acetyl-5-cyclohexyl-3-amino-1-(4-methylphenyl)-1,5-dihydro-2H-pyrrol-2-one |
| 01/06/2005 | US20050004165 Composition and method for modulating BAR/FXR receptor activity |
| 01/06/2005 | US20050004150 For therapy and prophylaxis of immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, proliferative disorders, immunologically-mediated diseases, or respiratory disorders |
| 01/06/2005 | US20050004142 furo(2,3-d)pyrimidine and thieno(2,3-d)pyrimidine compounds for treating cancer and hyperproliferative diseases; receptor tyrosine kinase inhibitors |
| 01/06/2005 | US20050004140 Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states |
| 01/06/2005 | US20050004135 Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| 01/06/2005 | US20050004132 Pain, immune diseases, inflammatory disorders; low toxicity; such as 1-[2-(3-(4-Pyridyl)phenyl)ethyl]-4-(3-(trifluoromethyl)phenyl)-1,2,3,6-tetrahydropyridine 1-oxide |
| 01/06/2005 | US20050004126 Method of determining potential allosterically-binding matrix metalloproteinase inhibitors |
| 01/06/2005 | US20050004125 Such as 4-[[4-(1-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]-benzonitrile; bipolar disorder, pain, type 2 diabetes |
| 01/06/2005 | US20050004120 Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents |
| 01/06/2005 | US20050004119 Trypsin like serine protease enzyme inhibitors |